familial adenomatous polyposis | GenomeWeb

familial adenomatous polyposis

Researchers identified two cases with biallelic mutations in MSH3 in exome sequences from more than 100 patients with unexplained colorectal adenomatous polyposis.

In individuals at risk of colorectal cancer, pre-cancerous adenomas contain somatic mutations affecting known cancer genes and pathways.

Restarting the trial will require the company to raise additional funds before its money runs out this summer.

With a portfolio of more mature technologies and increased interest in RNAi from the investment and pharmaceutical communities alike, Marina Biotech expects to rebuild itself as a leaner company with a greater focus on drug discovery, the struggling company’s top official said th

While RNAi drug developers continue to pursue major indications such as cancer and hepatitis C, a number of these companies are looking to niche diseases as good opportunities to apply the gene-silencing technology.

By Doug Macron
Marina Biotech this week announced that it will shortly begin enrolling the second cohort of patients in an ongoing phase Ib/IIa trial of its RNAi-based familial adenomatous polyposis treatment CEQ508.

The drug uses orally delivered attenuated Escherichia coli to transcribe shRNAs targeting beta-catenin, an oncogene that plays a role in the development of colorectal polyps that characterize the disease.

The move marks the company's foray into the ranks of clinical-stage drug developers and its first steps toward becoming a therapeutics marketer.

The drug is currently being tested in a phase Ia/IIb study.

FAP is an inherited, colorectal cancer syndrome characterized by the growth of colorectal polyps. Though the polyps are initially benign, they become malignant in nearly all cases in the absence of colectomy, according to Marina.

Pages

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.